SYRE Analyst Rating Maintained: Three Firms Raise Price Targets

Wall Street just sent a strong signal about Spyre Therapeutics, Inc. (SYRE). Three major analyst firms maintained their bullish stances while raising price targets on April 13, 2026. The SYRE analyst rating landscape shows consistent confidence from Wedbush, BTIG, and Jefferies. These firms didn’t downgrade or upgrade their ratings, but they did boost their price targets significantly. This tells us something important: analysts believe SYRE has more upside potential than they previously thought. For investors tracking the biotech sector, this coordinated action across multiple firms deserves attention.

Wedbush Maintains Outperform Rating with $80 Price Target

Wedbush’s Confidence Signal

Wedbush maintained its Outperform rating on SYRE while raising the price target to $80 from $65 on April 13 at 2:51 PM. This $15 increase represents a 23% upside from the previous target. Wedbush’s decision to keep the Outperform rating intact shows the firm sees sustained momentum in Spyre Therapeutics. The higher price target reflects improved confidence in the company’s pipeline and commercial execution.

What Outperform Means

An Outperform rating suggests the stock should beat the broader market over the next 12 months. Wedbush’s maintained stance combined with the raised target indicates the firm expects SYRE to deliver strong returns. This SYRE analyst rating from Wedbush provides a floor of confidence for long-term investors.

BTIG Raises Price Target to $98 with Buy Rating Intact

Aggressive Price Target Increase

BTIG maintained its Buy rating while raising the SYRE price target to $98 from $70 on April 13 at 2:23 PM. This $28 increase represents a 40% jump from the previous target. BTIG’s aggressive move signals the firm sees significant upside potential in Spyre Therapeutics. The Buy rating combined with the substantial price target increase shows BTIG remains one of the most bullish voices on SYRE.

Market Implications

BTIG’s $98 target is the highest among the three firms raising targets on this day. This SYRE analyst rating from BTIG suggests the firm believes the market is undervaluing the company’s prospects. Investors should note that BTIG’s confidence level appears higher than peers.

Jefferies Raises Target to $85 with Buy Rating Maintained

Significant Target Revision

Jefferies maintained its Buy rating while raising the SYRE price target to $85 from $47 on April 13 at 12:44 PM. This $38 increase represents an 81% jump from the previous target. Jefferies’ dramatic revision suggests the firm has gained new conviction about Spyre Therapeutics’ value. The Buy rating remains unchanged, but the higher target reflects improved visibility into the company’s prospects.

Analyst Conviction Shift

Jefferies’ 81% target increase is the largest percentage move among the three firms. This SYRE analyst rating change indicates Jefferies may have received new data or achieved better clarity on the company’s pipeline. The substantial revision shows meaningful confidence in SYRE’s near-term and medium-term performance.

Coordinated Analyst Action Signals Market Confidence

Three Firms, One Direction

On April 13, 2026, all three major firms raised their SYRE price targets without changing their ratings. This coordinated action is significant because it shows broad analyst agreement on upside potential. Wedbush, BTIG, and Jefferies collectively raised targets by an average of 48%. This SYRE analyst rating consistency across multiple firms strengthens the bullish case for investors.

What This Means for Investors

When multiple analysts raise targets simultaneously, it often reflects new positive developments or improved confidence. The maintained ratings suggest these firms already believed in SYRE’s story. The higher targets mean they now see more value than before. This pattern typically precedes positive stock performance.

Meyka AI Grade and Market Context

Meyka AI Assessment

Meyka AI rates SYRE with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The B+ grade reflects solid fundamentals and positive analyst sentiment. Meyka AI’s proprietary scoring aligns with the recent SYRE analyst rating actions from major firms.

Stock Performance and Analyst Targets

Despite the positive analyst moves, SYRE stock declined slightly after the announcements. The stock fell 1.98% following Wedbush’s target raise and 1.47% after BTIG’s announcement. These short-term declines don’t negate the longer-term bullish thesis from analysts. The SYRE price target increases suggest analysts expect recovery and appreciation over the next 12 months.

Understanding the SYRE Analyst Rating Landscape

Why Maintained Ratings Matter

When analysts maintain ratings while raising targets, it signals confidence without dramatic reversals. This SYRE analyst rating approach is more conservative than upgrades but still bullish. Maintained ratings suggest the firms already had conviction and are simply increasing their upside estimates. This pattern often indicates sustainable confidence rather than reactive enthusiasm.

Price Target Ranges

The three firms now have SYRE price targets ranging from $80 to $98. This $18 spread reflects different methodologies and assumptions about the company’s future. Jefferies’ $85 target sits in the middle, while BTIG’s $98 represents the most optimistic case. These SYRE analyst rating targets provide investors with a range of potential outcomes over the next year.

Final Thoughts

Three major analyst firms delivered a coordinated message about Spyre Therapeutics on April 13, 2026: the company has more upside than previously thought. Wedbush, BTIG, and Jefferies all maintained their bullish ratings while raising price targets by an average of 48%. Wedbush’s $80 target, BTIG’s $98 target, and Jefferies’ $85 target create a compelling range for investors. The SYRE analyst rating consistency across multiple firms strengthens confidence in the company’s prospects. Meyka AI rates SYRE with a B+, reflecting solid fundamentals and positive analyst consensus. While short-term stock declines followed the announcements, the maintained ratings combined with higher targets suggest analysts expect meaningful appreciation over the next 12 months. These rating actions remind us that analyst consensus often precedes market moves. When multiple firms raise targets simultaneously, it typically signals they’ve identified genuine value that the market hasn’t fully recognized yet.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.